{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:41:27Z","timestamp":1783338087933,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.nmd.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T17:02:21Z","timestamp":1642093341000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Maren","family":"Winkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"von Landenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-858X","authenticated-orcid":false,"given":"Katharina","family":"Kuchenbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-6877","authenticated-orcid":false,"given":"Jens","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0111-7281","authenticated-orcid":false,"given":"Cornelia","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160C","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0002","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.nmd.2022.01.001_bib0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2022.01.001_bib0004","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe Registry","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet Part A"},{"issue":"15","key":"10.1016\/j.nmd.2022.01.001_bib0005","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nmd.2022.01.001_bib0006","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol."},{"issue":"5","key":"10.1016\/j.nmd.2022.01.001_bib0008","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2022.01.001_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","article-title":"Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study","volume":"35","author":"Furusawa","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2022.01.001_bib0010","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","author":"Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0011","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"issue":"23","key":"10.1016\/j.nmd.2022.01.001_bib0012","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.nmd.2022.01.001_bib0013","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.nmd.2022.01.001_bib0014","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2022.01.001_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"5 Pt 1","key":"10.1016\/j.nmd.2022.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ptj\/64.1.41","article-title":"Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures","volume":"64","author":"Florence","year":"1984","journal-title":"Phys Ther"},{"issue":"2","key":"10.1016\/j.nmd.2022.01.001_bib0018","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients","volume":"35","author":"van Capelle","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0019","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS Statement on respiratory muscle testing","volume":"166","author":"Society","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.nmd.2022.01.001_bib0021","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","article-title":"Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy","volume":"41","author":"van der Meijden","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nmd.2022.01.001_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"A Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"10.1016\/j.nmd.2022.01.001_bib0023","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0024","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0025","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nmd.2022.01.001_bib0026","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":"Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease","volume":"19","author":"Van der Beek","year":"2009","journal-title":"Neuromuscul Disord"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2022.01.001_bib0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2022.01.001_bib0028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.nmd.2022.01.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158912","article-title":"Quantification of diaphragm mechanics in pompe disease using dynamic 3D MRI","volume":"11","author":"Mogalle","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.nmd.2022.01.001_bib0030","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0031","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2022.01.001_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-015-0243-x","article-title":"Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease","volume":"3","author":"Schaaf","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.nmd.2022.01.001_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2022.01.001_bib0036","doi-asserted-by":"crossref","first-page":"36182","DOI":"10.1038\/srep36182","article-title":"French Pompe Registry Study Group. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients","volume":"6","author":"Masat","year":"2016","journal-title":"Sci Rep."},{"issue":"4","key":"10.1016\/j.nmd.2022.01.001_bib0037","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0272-2712(18)30604-8","article-title":"Serum enzymes in disease of skeletal muscle","volume":"9","author":"Rosalki","year":"1989","journal-title":"Clin Lab Med"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:47Z","timestamp":1760775107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0960896622000013"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.01.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}